Class IIIOngoingD-0468-2024
Drug recall · May 1, 2024
Abilify recall
Why: Cross Contamination with Other Products
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Abilify (aripiprazole), 15 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-009-13
- Lots / codes
Lot # AMS00223A, Exp 07/31/2025
- Quantity
- N/A
- Company
- Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd., Tokushima, N/A
- Distribution
- USA nationwide.
- Initiated
- April 9, 2024 · Voluntary: Firm initiated
- Classified
- April 23, 2024
- Reported
- May 1, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Class IIIOngoingMay 1, 2024AbilifySecond Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. · D-0466-2024Class IIIOngoingMay 1, 2024AbilifySecond Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. · D-0467-2024Class IIIOngoingMay 1, 2024AbilifySecond Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. · D-0469-2024
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Abilify
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.